BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8985085)

  • 1. Complement-regulatory proteins in ovarian malignancies.
    Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
    Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.
    Bjørge L; Junnikkala S; Kristoffersen EK; Hakulinen J; Matre R; Meri S
    Br J Cancer; 1997; 75(9):1247-55. PubMed ID: 9155042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
    Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
    APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes.
    Taylor CT; Johnson PM
    Mol Hum Reprod; 1996 Jan; 2(1):52-9. PubMed ID: 9238658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
    Bjørge L; Jensen TS; Matre R
    Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
    Iborra A; Mayorga M; Llobet N; Martínez P
    Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.
    Sakuma T; Kodama K; Hara T; Eshita Y; Shibata N; Matsumoto M; Seya T; Mori Y
    Jpn J Cancer Res; 1993 Jul; 84(7):753-9. PubMed ID: 7690355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
    Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of complement regulatory proteins on islets of Langerhans: a comparison between human islets and islets isolated from normal and hDAF transgenic pigs.
    Bennet W; Björkland A; Sundberg B; Brandhorst D; Brendel MD; Richards A; White DJ; Nilsson B; Groth CG; Korsgren O
    Transplantation; 2001 Jul; 72(2):312-9. PubMed ID: 11477359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the complement regulatory proteins CD46, CD55, and CD59 in human fallopian tube, endometrium, and cervical mucosa and secretion.
    Jensen TS; Bjørge L; Wollen AL; Ulstein M
    Am J Reprod Immunol; 1995 Jul; 34(1):1-9. PubMed ID: 7576125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell surface regulators of complement, 5I2 antigen, and CD59, in the rat eye and adnexal tissues.
    Bardenstein DS; Cheyer C; Okada N; Morgan BP; Medof ME
    Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):519-24. PubMed ID: 9950613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
    Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
    Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.